In Depth 24 Jul 2023 Sarcoma research: is a breakthrough in sight? Among the rarest forms of cancers, sarcomas develop in the bones and connective tissues that support structures in the body like blood vessels, nerves and joints. This year, around 13,400 new cases of soft tissue sarcomas are estimated to be diagnosed in the U.S. alone, according to the American Cancer Society. As July marks Sarcoma […] July 24, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2023 FDA clears T-Cell receptor natural killer cell therapy for sarcoma Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2023Beyond Biotech podcast 35: Rare Disease Day As February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO Biosciences; Stefano Portolano, chief executive officer, Azafaros; and from Replay, Adrian Woolfson, executive chairman, president, and co-founder, and Lachlan MacKinnon, CEO and co-founder. Rare Disease […] February 24, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Syena created to deliver first-in-class TCR-NK cell therapy Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […] February 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Replay targets genetic brain disorders with new gene therapy company, Kaleibe Replay, a genome writing company, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders. It is the third of Replay’s product companies to launch since the company’s formation in July and will leverage Replay’s high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, to target genetic brain disorders. […] December 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Replay receives $1.5M grant for hypoimmunogenic technology platform Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […] November 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 New Replay HSV gene therapy company Telaria to focus on skin diseases Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Telaria’s co-founders are HSV scientists, entrepreneurs, and specialists in genetic skin diseases. In addition to Joe Glorioso, Telaria’s […] November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Replay Bio launches HSV gene therapy company to target retinal eye disease Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […] October 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email